Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity.

dc.centroFacultad de Medicinaes_ES
dc.contributor.authorPosadas, Sinforiano Jose
dc.contributor.authorPadial, Antonia
dc.contributor.authorTorres-Jaén, María Josefa
dc.contributor.authorMayorga Mayorga, Cristobalina
dc.contributor.authorLeyva-Fernández, Laura
dc.contributor.authorSánchez, Elena
dc.contributor.authorÁlvarez, Javier
dc.contributor.authorRomano, Antonino
dc.contributor.authorJuárez, Carlos
dc.contributor.authorBlanca, Miguel
dc.contributor.authorSánchez, Elena
dc.date.accessioned2024-09-17T11:06:31Z
dc.date.available2024-09-17T11:06:31Z
dc.date.issued2002
dc.departamentoFarmacología y Pediatría
dc.descriptionPolítica de acceso abierto tomada de:https://v2.sherpa.ac.uk/id/publication/3193es_ES
dc.description.abstractBackground Drugs can induce different immunologic reactions; T-cell mediated responses produce the most severe reactions. Although in vitro studies show that T cells recognize drugs or their metabolites and induce an effector cytotoxic response, direct in vivo evidence of involvement is lacking. T lymphocytes produce cytotoxic markers that are responsible for 2 major pathways to cell death: granule-mediated exocytosis (perforin and granzyme B) and Fas/FasL interaction. Objective: The purpose of this investigation was to establish the role of proinflammatory TNF-α and cytotoxic markers in subjects with delayed responses to drugs. Methods: We assessed expression levels by quantitative-competitive PCR of TNF-α, perforin, granzyme B, and FasL in mononuclear cells from peripheral blood and blister fluid from subjects with delayed reactions to drugs. Samples were obtained within 24 hours of the reaction and 30 days later. Fifteen patients were included and classified according to severity of the reaction, as follows: (A) maculopapular exanthema, (B) desquamative exanthema, (C) Stevens-Johnson syndrome, (D) toxic epidermal necrolysis. Results: At the acute stage, there was a large increase in TNF-α (9-fold), perforin (6-fold), and GrB (7-fold) in patients in comparison with control subjects. FasL was expressed in PBMCs only in Stevens-Johnson syndrome and toxic epidermal necrolysis. A high association between cytotoxic markers and disease severity was seen (P < .001). Conclusions. Our data show that TNF-α, perforin, GrB, and FasL are increased in the early stage of disease, suggesting that a cytotoxic mechanism might be taking part. These findings support the role of T cells in allergic drug reactions and provide further clues pertaining to therapeutic interventions.es_ES
dc.identifier.citationPosadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002 Jan;109(1):155-61. PMID:11799383es_ES
dc.identifier.doi10.1067/mai.2002.120563
dc.identifier.urihttps://hdl.handle.net/10630/32580
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAlergia a los medicamentoses_ES
dc.subjectDermatitis medicamentosaes_ES
dc.subject.otherFas-Les_ES
dc.subject.otherDrugses_ES
dc.subject.otherAllergyes_ES
dc.subject.otherPerforines_ES
dc.subject.otherGranzyme Bes_ES
dc.titleDelayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationabcd4607-b47d-4018-86ad-3b5f76cbee1e
relation.isAuthorOfPublication90dc288c-2403-4516-b966-5b83e114abcd
relation.isAuthorOfPublication.latestForDiscoveryabcd4607-b47d-4018-86ad-3b5f76cbee1e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JACI 2002 Perforina Granzima.pdf
Size:
616.91 KB
Format:
Adobe Portable Document Format
Description:
versión postprint J Allergy Clin Immunol. 2002 Jan;109(1):155-61.
Download

Description: versión postprint J Allergy Clin Immunol. 2002 Jan;109(1):155-61.

Collections